{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Liu Y"],"funding":["National Natural Science Foundation of China"],"pagination":["1072170"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10020617"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14"],"pubmed_abstract":["<h4>Background</h4>Women who have polycystic ovary syndrome (PCOS) with high body mass index (BMI) typically have an attenuated ovarian response and decreased follicular size, which are linked to unfavourable clinical outcomes following <i>in vitro</i> fertilization (IVF) therapy. The follicular output rate (FORT), a qualitative indicator of follicular response, seems to be positively linked to the clinical outcomes of IVF. Progestin-primed ovarian stimulation (PPOS) has become an alternative to gonadotropin-releasing hormone (GnRH) analogues to inhibit the premature luteinizing hormone (LH) surge. As letrozole (LE) shows promise in enhancing ovarian response, we compared PPOS with and without LE for PCOS in high BMI women with a focus on the FORT and associated clinical and pregnancy outc"],"journal":["Frontiers in endocrinology"],"pubmed_title":["Letrozole cotreatment improves the follicular output rate in high-body-mass-index women with polycystic ovary syndrome undergoing IVF treatment."],"pmcid":["PMC10020617"],"funding_grant_id":["82001502, 81903324, 82273634"],"pubmed_authors":["Liu Y","Lin J","Shen X","Zhu Q","Kuang Y"],"additional_accession":[]},"is_claimable":false,"name":"Letrozole cotreatment improves the follicular output rate in high-body-mass-index women with polycystic ovary syndrome undergoing IVF treatment.","description":"<h4>Background</h4>Women who have polycystic ovary syndrome (PCOS) with high body mass index (BMI) typically have an attenuated ovarian response and decreased follicular size, which are linked to unfavourable clinical outcomes following <i>in vitro</i> fertilization (IVF) therapy. The follicular output rate (FORT), a qualitative indicator of follicular response, seems to be positively linked to the clinical outcomes of IVF. Progestin-primed ovarian stimulation (PPOS) has become an alternative to gonadotropin-releasing hormone (GnRH) analogues to inhibit the premature luteinizing hormone (LH) surge. As letrozole (LE) shows promise in enhancing ovarian response, we compared PPOS with and without LE for PCOS in high BMI women with a focus on the FORT and associated clinical and pregnancy outc","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023","modification":"2026-06-03T15:17:07.56Z","creation":"2024-11-13T09:30:07.219Z"},"accession":"S-EPMC10020617","cross_references":{"pubmed":["36936138"],"doi":["10.3389/fendo.2023.1072170"]}}